These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15086599)

  • 21. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions.
    Quiles-Pérez R; Muñoz-de-Rueda P; Maldonado AM; Martín-Álvarez A; Quer J; Salmerón J
    J Med Virol; 2014 Nov; 86(11):1886-97. PubMed ID: 25091333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.
    Nakagawa M; Sakamoto N; Ueyama M; Mogushi K; Nagaie S; Itsui Y; Azuma S; Kakinuma S; Tanaka H; Enomoto N; Watanabe M
    J Gastroenterol; 2010 Jun; 45(6):656-65. PubMed ID: 20112032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
    Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
    Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
    Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection.
    Mihm S; Monazahian M; Grethe S; Fechner C; Ramadori G; Thomssen R
    J Med Virol; 1999 Jul; 58(3):227-34. PubMed ID: 10447417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreatment sera of HCV-chronically infected patients and their effect on the result of treatment.
    Kmieciak D; Kruszyna Ł; Migdalski P; Łaciński M; Juszczyk J; Trzeciak WH
    Jpn J Infect Dis; 2006 Apr; 59(2):92-9. PubMed ID: 16632908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
    Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
    J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b.
    Hofgärtner WT; Polyak SJ; Sullivan DG; Carithers RL; Gretch DR
    J Med Virol; 1997 Oct; 53(2):118-26. PubMed ID: 9334922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
    Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
    Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.
    Sarrazin C; Berg T; Lee JH; Teuber G; Dietrich CF; Roth WK; Zeuzem S
    J Hepatol; 1999 Jun; 30(6):1004-13. PubMed ID: 10406177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
    Yahoo N; Sabahi F; Shahzamani K; Malboobi MA; Jabbari H; Sharifi H; Mousavi-Fard SH; Merat S
    J Med Virol; 2011 Aug; 83(8):1332-7. PubMed ID: 21678437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NS5A mutations predict biochemical but not virological response to interferon-alpha treatment of sporadic hepatitis C virus infection in European patients.
    Stratidaki I; Skoulika E; Kelefiotis D; Matrella E; Alexandrakis G; Economou A; Kouroumalis E
    J Viral Hepat; 2001 Jul; 8(4):243-8. PubMed ID: 11454174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin.
    Cappiello G; Abbate I; Lo Iacono O; Longo R; Solmone M; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxi A; Ippolito G; Capobianchi MR
    Antivir Ther; 2003 Apr; 8(2):105-10. PubMed ID: 12741622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein.
    Ali I; Khan S; Attaullah S; Khan SN; Khan J; Siraj S; Iqbal A; Swati ZA; Idrees M
    Virol J; 2011 May; 8():258. PubMed ID: 21609495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.
    Puig-Basagoiti F; Sáiz JC; Forns X; Ampurdanès S; Giménez-Barcons M; Franco S; Sánchez-Fueyo A; Costa J; Sánchez-Tapias JM; Rodés J
    J Med Virol; 2001 Sep; 65(1):35-44. PubMed ID: 11505441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The NS5a gene of hepatitis C virus in patients treated with interferon-alpha.
    McKechnie VM; Mills PR; McCruden EA
    J Med Virol; 2000 Apr; 60(4):367-78. PubMed ID: 10686018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b].
    Jin YJ; Park YK; Yun GJ; Lee HC; Jeong SH; Kim GM; Lim YS; Chung YH; Lee YS; Suh DJ
    Korean J Hepatol; 2010 Jun; 16(2):158-67. PubMed ID: 20606500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.
    Goyal A; Hofmann WP; Hermann E; Traver S; Hissar SS; Arora N; Blum HE; Zeuzem S; Sarrazin C; Sarin SK
    Med Microbiol Immunol; 2007 Mar; 196(1):11-21. PubMed ID: 16955308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.